ProKidney Corp. (NASDAQ:PROK) SVP Sells $145,498.19 in Stock

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 84,103 shares of ProKidney stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $1.73, for a total value of $145,498.19. Following the sale, the senior vice president now directly owns 189,670 shares in the company, valued at approximately $328,129.10. The sale was disclosed in a document filed with the SEC, which is available at this link.

ProKidney Trading Up 1.1 %

PROK stock traded up $0.03 during trading on Wednesday, hitting $2.75. The company had a trading volume of 3,070,453 shares, compared to its average volume of 635,572. The company has a fifty day moving average price of $1.53 and a two-hundred day moving average price of $1.80. The company has a market cap of $630.69 million, a P/E ratio of -5.18 and a beta of 1.08. ProKidney Corp. has a fifty-two week low of $1.12 and a fifty-two week high of $13.51.

ProKidney (NASDAQ:PROK) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.10. On average, analysts expect that ProKidney Corp. will post -0.65 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PROK. Bank of America lowered ProKidney from a “buy” rating to a “neutral” rating in a report on Tuesday, January 2nd. Morgan Stanley began coverage on ProKidney in a report on Thursday, March 7th. They set an “equal weight” rating and a $3.00 price objective on the stock.

Institutional Trading of ProKidney

Several institutional investors have recently bought and sold shares of PROK. BlackRock Inc. raised its position in ProKidney by 978.2% in the 2nd quarter. BlackRock Inc. now owns 3,316,973 shares of the company’s stock valued at $37,117,000 after purchasing an additional 3,009,342 shares during the last quarter. State Street Corp raised its position in shares of ProKidney by 1,540.0% during the second quarter. State Street Corp now owns 990,259 shares of the company’s stock worth $11,081,000 after acquiring an additional 929,878 shares during the last quarter. Geode Capital Management LLC raised its position in shares of ProKidney by 450.9% during the second quarter. Geode Capital Management LLC now owns 760,823 shares of the company’s stock worth $8,514,000 after acquiring an additional 622,728 shares during the last quarter. Morgan Stanley raised its position in shares of ProKidney by 5.8% during the fourth quarter. Morgan Stanley now owns 10,947,495 shares of the company’s stock worth $75,100,000 after acquiring an additional 595,839 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of ProKidney by 1,451.6% during the second quarter. Northern Trust Corp now owns 452,186 shares of the company’s stock worth $5,060,000 after acquiring an additional 423,043 shares during the last quarter. Institutional investors and hedge funds own 51.59% of the company’s stock.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.